The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).
Terragna C, Remondini D, Martello M, Zamagni E, Pantani L, Patriarca F, Pezzi A, Levi G, Offidani M, Proserpio I, De Sabbata G, Tacchetti P, Cangialosi C, Ciambelli F, Viganò CV, Dico FA, Santacroce B, Borsi E, Brioli A, Marzocchi G, Castellani G, Martinelli G, Palumbo A, Cavo M.
Terragna C, et al. Among authors: tacchetti p.
Oncotarget. 2016 Mar 1;7(9):9666-79. doi: 10.18632/oncotarget.5718.
Oncotarget. 2016.
PMID: 26575327
Free PMC article.